Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 ( ...

The future of cell therapy. Corporate Overview September 15, 2021 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and there can be no assurance as to its accu ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Ioana Hone – Director of Investor Relations Brian Culley – Chief Executive Officer Kevin Cook – Chief Financial Officer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Joe Pantginis – H.C. Wainwright Dane Leone – RJF Operator Welcome to the Lineage Cell Therapeutics’ Second Quarter 2021 Conference Call. At this time, all participants are in a listen-only mode. An audio ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (State ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Ioana Hone - Director of Investor Relations Brian Culley - Chief Executive Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Joe Pantginis - H.C. Wainwright Robert LeBoyer - Noble Capital Keay Nakae - Chardan Operator Welcome to the Lineage Cell Therapeutics’ First Quarter 2021 Conference Call. At this time, all participants are in a listen only mode. An audio webca ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) California 94-3127919 (Stat ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants Ioana Hone – Director-Investor Relations Brian Culley – Chief Executive Officer Brandi Roberts – Chief Financial Officer Conference Call Participants Joe Pantginis – H.C. Wainwright Jason McCarthy – Maxim Group Keay Nakae – Chardan Operator Ladies and gentlemen welcome to the Lineage Cell Therapeutics' Fourth Quarter and Year End 2020 Conference Call. At this time, all participants are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___________ to __________ Commission file number 001-12830 Lineage Cell Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

The future of cell therapy. Corporate Overview January 6, 2021 Forward-Looking Statements This presentation is for informational purposes only and is not an offer to sell or a solicitation of an offer to buy any securities of Lineage Cell Therapeutics, Inc. ("Lineage"). This presentation includes certain information obtained from trade and statistical services, third-party publications, and other sources. Lineage has not independently verified such information and there can be no assurance as to its accurac ...

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) Q3 2020 Results Earnings Conference Call November 4, 2020 4:30 PM ET Company Participants Ioana Hone - Director, Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Conference Call Participants Jason McCarthy - Maxim Group LLC Joseph Pantginis - H.C. Wainwright & Co., LLC Ahu Demir - Noble Life Science Partners Keay Nakae - Chardan Capital Markets Operator Welcome to the Lineage Cell Therapeutics Third Quarter 2020 Co ...